Aggarwal V, Workman CJ, Vignali DAA (2023) LAG-3 as the third checkpoint inhibitor. Nat Immunol 24:1415–1422. https://doi.org/10.1038/s41590-023-01569-z

Article  CAS  PubMed  Google Scholar 

Alvi RM, Frigault MJ, Fradley MG, Jain MD, Mahmood SS, Awadalla M, Lee DH, Zlotoff DA, Zhang L, Drobni ZD, Hassan MZO, Bassily E, Rhea I, Ismail-Khan R, Mulligan CP, Banerji D, Lazaryan A, Shah BD, Rokicki A, Raje N, Chavez JC, Abramson J, Locke FL, Neilan TG (2019) Cardiovascular events among adults treated with chimeric antigen receptor T-Cells (CAR-T). J Am Coll Cardiol 74:3099–3108. https://doi.org/10.1016/j.jacc.2019.10.038

Article  CAS  PubMed  Google Scholar 

Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Yokoi T, Chiappori A, Lee KH, de Wit M, Cho BC, Bourhaba M, Quantin X, Tokito T, Mekhail T, Planchard D, Kim Y-C, Karapetis CS, Hiret S, Ostoros G, Kubota K, Gray JE, Paz-Ares L, de Castro CJ, Wadsworth C, Melillo G, Jiang H, Huang Y, Dennis PA, Özgüroğlu M, PACIFIC Investigators (2017) Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med 377:1919–1929. https://doi.org/10.1056/NEJMoa1709937

Article  CAS  PubMed  Google Scholar 

Awadalla M, Mahmood SS, Groarke JD, Hassan MZO, Nohria A, Rokicki A, Murphy SP, Mercaldo ND, Zhang L, Zlotoff DA, Reynolds KL, Alvi RM, Banerji D, Liu S, Heinzerling LM, Jones-O’Connor M, Bakar RB, Cohen JV, Kirchberger MC, Sullivan RJ, Gupta D, Mulligan CP, Shah SP, Ganatra S, Rizvi MA, Sahni G, Tocchetti CG, Lawrence DP, Mahmoudi M, Devereux RB, Forrestal BJ, Mandawat A, Lyon AR, Chen CL, Barac A, Hung J, Thavendiranathan P, Picard MH, Thuny F, Ederhy S, Fradley MG, Neilan TG (2020) Global longitudinal strain and cardiac events in patients with immune checkpoint inhibitor-related myocarditis. J Am Coll Cardiol 75:467–478. https://doi.org/10.1016/j.jacc.2019.11.049

Article  CAS  PubMed  Google Scholar 

Axelrod ML, Meijers WC, Screever EM, Qin J, Carroll MG, Sun X, Tannous E, Zhang Y, Sugiura A, Taylor BC, Hanna A, Zhang S, Amancherla K, Tai W, Wright JJ, Wei SC, Opalenik SR, Toren AL, Rathmell JC, Ferrell PB, Phillips EJ, Mallal S, Johnson DB, Allison JP, Moslehi JJ, Balko JM (2022) T cells specific for α-myosin drive immunotherapy-related myocarditis. Nature 611:818–826. https://doi.org/10.1038/s41586-022-05432-3

Article  CAS  PubMed  Google Scholar 

Barlesi F, Vansteenkiste J, Spigel D, Ishii H, Garassino M, de Marinis F, Özgüroğlu M, Szczesna A, Polychronis A, Uslu R, Krzakowski M, Lee J-S, Calabrò L, Arén Frontera O, Ellers-Lenz B, Bajars M, Ruisi M, Park K (2018) Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study. Lancet Oncol 19:1468–1479. https://doi.org/10.1016/S1470-2045(18)30673-9

Article  CAS  PubMed  Google Scholar 

Battisti NML, Andres MS, Lee KA, Ramalingam S, Nash T, Mappouridou S, Senthivel N, Asavisanu K, Obeid M, Tripodaki E-S, Angelis V, Fleming E, Goode EF, John S, Rosen SD, Allen M, Stanway S, Lyon AR, Ring A (2021) Incidence of cardiotoxicity and validation of the Heart Failure Association-International Cardio-Oncology Society risk stratification tool in patients treated with trastuzumab for HER2-positive early breast cancer. Breast Cancer Res Treat 188:149–163. https://doi.org/10.1007/s10549-021-06192-w

Article  CAS  PubMed  Google Scholar 

Beaulieu E, Spanjaart A, Roes A, Rachet B, Dalle S, Kersten MJ, Maucort-Boulch D, Jalali MS (2022) Health-related quality of life in cancer immunotherapy: a systematic perspective, using causal loop diagrams. Qual Life Res Int J Qual Life Asp Treat Care Rehabil 31:2357–2366. https://doi.org/10.1007/s11136-022-03110-5

Article  Google Scholar 

Bishop MR, Dickinson M, Purtill D, Barba P, Santoro A, Hamad N, Kato K, Sureda A, Greil R, Thieblemont C, Morschhauser F, Janz M, Flinn I, Rabitsch W, Kwong Y-L, Kersten MJ, Minnema MC, Holte H, Chan EHL, Martinez-Lopez J, Müller AMS, Maziarz RT, McGuirk JP, Bachy E, Le Gouill S, Dreyling M, Harigae H, Bond D, Andreadis C, McSweeney P, Kharfan-Dabaja M, Newsome S, Degtyarev E, Awasthi R, Del Corral C, Andreola G, Masood A, Schuster SJ, Jäger U, Borchmann P, Westin JR (2022) Second-line tisagenlecleucel or standard care in aggressive B-cell lymphoma. N Engl J Med 386:629–639. https://doi.org/10.1056/NEJMoa2116596

Article  CAS  PubMed  Google Scholar 

Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, Barlesi F, Kohlhäufl M, Arrieta O, Burgio MA, Fayette J, Lena H, Poddubskaya E, Gerber DE, Gettinger SN, Rudin CM, Rizvi N, Crinò L, Blumenschein GR, Antonia SJ, Dorange C, Harbison CT, Graf Finckenstein F, Brahmer JR (2015) Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 373:1627–1639. https://doi.org/10.1056/NEJMoa1507643

Article  CAS  PubMed  PubMed Central  Google Scholar 

Brahmer JR, Abu-Sbeih H, Ascierto PA, Brufsky J, Cappelli LC, Cortazar FB, Gerber DE, Hamad L, Hansen E, Johnson DB, Lacouture ME, Masters GA, Naidoo J, Nanni M, Perales M-A, Puzanov I, Santomasso BD, Shanbhag SP, Sharma R, Skondra D, Sosman JA, Turner M, Ernstoff MS (2021) Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. J Immunother Cancer 9:e002435. https://doi.org/10.1136/jitc-2021-002435

Article  PubMed  PubMed Central  Google Scholar 

Buehning F, Lerchner T, Vogel J, Hendgen-Cotta UB, Totzeck M, Rassaf T, Michel L (2024) Preclinical models of cardiotoxicity from immune checkpoint inhibitor therapy. Basic Res Cardiol. https://doi.org/10.1007/s00395-024-01070-0

Article  PubMed  Google Scholar 

Burns EA, Gentille C, Trachtenberg B, Pingali SR, Anand K (2021) Cardiotoxicity associated with Anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy: recognition, risk factors, and management. Dis Basel Switz 9:20. https://doi.org/10.3390/diseases9010020

Article  CAS  Google Scholar 

Cautela J, Zeriouh S, Gaubert M, Bonello L, Laine M, Peyrol M, Paganelli F, Lalevee N, Barlesi F, Thuny F (2020) Intensified immunosuppressive therapy in patients with immune checkpoint inhibitor-induced myocarditis. J Immunother Cancer 8:e001887. https://doi.org/10.1136/jitc-2020-001887

Article  PubMed  PubMed Central  Google Scholar 

Chen J, Jiang CC, Jin L, Zhang XD (2016) Regulation of PD-L1: a novel role of pro-survival signalling in cancer. Ann Oncol Off J Eur Soc Med Oncol 27:409–416. https://doi.org/10.1093/annonc/mdv615

Article  CAS  Google Scholar 

Correale P, Saladino RE, Giannarelli D, Sergi A, Mazzei MA, Bianco G, Giannicola R, Iuliano E, Forte IM, Calandruccio ND, Falzea AC, Strangio A, Nardone V, Pastina P, Tini P, Luce A, Caraglia M, Caracciolo D, Mutti L, Tassone P, Pirtoli L, Giordano A, Tagliaferri P (2020) HLA expression correlates to the risk of immune checkpoint inhibitor-induced pneumonitis. Cells 9:1964. https://doi.org/10.3390/cells9091964

Article  CAS  PubMed  PubMed Central  Google Scholar 

D’Souza M, Nielsen D, Svane IM, Iversen K, Rasmussen PV, Madelaire C, Fosbøl E, Køber L, Gustafsson F, Andersson C, Gislason G, Torp-Pedersen C, Schou M (2021) The risk of cardiac events in patients receiving immune checkpoint inhibitors: a nationwide Danish study. Eur Heart J 42:1621–1631. https://doi.org/10.1093/eurheartj/ehaa884

Article  PubMed  Google Scholar 

Durham NM, Nirschl CJ, Jackson CM, Elias J, Kochel CM, Anders RA, Drake CG (2014) Lymphocyte activation gene 3 (LAG-3) modulates the ability of CD4 T-cells to be suppressed in vivo. PLoS ONE 9:e109080. https://doi.org/10.1371/journal.pone.0109080

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ettinghausen SE, Puri RK, Rosenberg SA (1988) Increased vascular permeability in organs mediated by the systemic administration of lymphokine-activated killer cells and recombinant interleukin-2 in mice. J Natl Cancer Inst 80:177–188. https://doi.org/10.1093/jnci/80.3.177

Article  CAS  PubMed  Google Scholar 

Fenioux C, Abbar B, Boussouar S, Bretagne M, Power JR, Moslehi JJ, Gougis P, Amelin D, Dechartres A, Lehmann LH, Courand P-Y, Cautela J, Alexandre J, Procureur A, Rozes A, Leonard-Louis S, Qin J, International ICI-Myocarditis Registry, Caheynier R, Charmeteau-De Muylder B, Redheuil A, Tubach F, Cadranel J, Milon A, Ederhy S, Similowski T, Johnson DB, Pizzo I, Catalan T, Benveniste O, Hayek SS, Allenbach Y, Rosenzwajg M, Dolladille C, Salem J-E (2023) Thymus alterations and susceptibility to immune checkpoint inhibitor myocarditis. Nat Med 29:3100–3110. https://doi.org/10.1038/s41591-023-02591-2

Article  CAS  PubMed  Google Scholar 

Finke D, Heckmann MB, Herpel E, Katus HA, Haberkorn U, Leuschner F, Lehmann LH (2021) Early detection of checkpoint inhibitor-associated myocarditis using 68Ga-FAPI PET/CT. Front Cardiovasc Med 8:614997. https://doi.org/10.3389/fcvm.2021.614997

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ganatra S, Redd R, Hayek SS, Parikh R, Azam T, Yanik GA, Spendley L, Nikiforow S, Jacobson C, Nohria A (2020) Chimeric antigen receptor T-cell therapy-associated cardiomyopathy in patients with refractory or relapsed non-Hodgkin lymphoma. Circulation 142:1687–1690. https://doi.org/10.1161/CIRCULATIONAHA.120.048100

Article  CAS  PubMed  Google Scholar 

Gergely TG, Drobni ZD, Sayour NV, Ferdinandy P, Varga ZV (2024) Molecular fingerprints of cardiovascular toxicities of immune checkpoint inhibitors. Basic Res Cardiol. https://doi.org/10.1007/s00395-024-01068-8

Article  PubMed  Google Scholar 

Goitein O, Matetzky S, Beinart R, Di Segni E,